Bruce G. Redman, DO | Authors

HOMETOWN PHARMACY

552 AUGUSTA DR

Articles

Immunotherapy in Renal Cell Carcinoma

June 01, 1999

Very little has changed in the management of advanced renal cell carcinoma since the approval of interleukin-2 (IL-2, aldesleukin [Proleukin]) in 1992 by the FDA for the systemic treatment of this disease. Dr. Bukowski succinctly reviews the